Therapies in development for castrate-resistant prostate cancer

Abstract

The paucity of active medical therapies for advanced prostate cancer underlies a critical need for clinical research in this area. Multiple new treatments are being evaluated, including therapies that target adrenal androgens, such as abiraterone; new chemotherapies, such as the oral platinum analog, satraplatin, and an epothilone analog, ixabepilone; combinations of chemotherapy with other agents, such as the VEGF inhibitor, bevacizumab, and calcitriol; as well as multiple immunotherapeutics, including sipuleucel-T, GVAX and ipilimumab. This review will highlight the promise of these new approaches and the challenges to their development.

Keywords::

• abiraterone
• adrenal androgens
• atrasentan
• bevacizumab
• calcitriol
• castrate-resistant prostate cancer
• chemotherapy
• GVAX
• immunotherapy
• ipilimumab
• ixabepilone
• Phase II
• satraplatin
• sipuleucel-T

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.